Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare

BMC Cancer

Robert I Griffiths¹  Mark D Danese²  Michelle L Gleeson²  José M Valderas¹ 

[1] Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

[2] Department of Epidemiology, Outcomes Insights, Inc, 340 N. Westlake Blvd, Suite 200, Westlake Village, CA 91362, USA

关键词: Survival;    Mortality;    Stage;    Risk factors;    Previously undiagnosed;    Diabetes;    Breast cancer;   

Others  :  1080001
DOI  :  10.1186/1471-2407-12-613

 received in 2012-09-05, accepted in 2012-12-19,  发布年份 2012

【 摘 要 】

Background

In breast cancer, diabetes diagnosed prior to cancer (previously diagnosed) is associated with advanced cancer stage and increased mortality. However, in the general population, 40% of diabetes is undiagnosed until glucose testing, and evidence suggests one consequence of increased evaluation and management around breast cancer diagnosis is the increased detection of previously undiagnosed diabetes. Biological factors – for instance, higher insulin levels due to untreated disease - and others underlying the association between previously diagnosed diabetes and breast cancer could differ in those whose diabetes remains undiagnosed until cancer. Our objectives were to identify factors associated with previously undiagnosed diabetes in breast cancer, and to examine associations between previously undiagnosed diabetes and cancer stage, treatment patterns, and mortality.

Methods

Using Surveillance, Epidemiology, and End Results-Medicare, we identified women diagnosed with breast cancer and diabetes between 01/2001 and 12/2005. Diabetes was classified as previously diagnosed if it was identified within Medicare claims between 24 and 4 months before cancer diagnosis, and previously undiagnosed if it was identified from 3 months before to ≤ 3 months after cancer. Patients were followed until 12/2007 or death, whichever came first. Multivariate analyses were performed to examine risk factors for previously undiagnosed diabetes and associations between undiagnosed (compared to previously diagnosed) diabetes, cancer stage, treatment, and mortality.

Results

Of 2,418 patients, 634 (26%) had previously undiagnosed diabetes; the remainder had previously diagnosed diabetes. The mean age was 77.8 years, and 49.4% were diagnosed with in situ or stage I disease. Age > 80 years (40% of the cohort) and limited health system contact (primary care physician and/or preventive services) prior to cancer were associated with higher adjusted odds of previously undiagnosed diabetes. Previously undiagnosed diabetes was associated with higher adjusted odds of advanced stage (III/IV) cancer (Odds Ratio = 1.37: 95% Confidence Interval (CI) 1.05 – 1.80; P = 0.02), and a higher adjusted mortality rate due to causes other than cancer (Hazard Ratio = 1.29; 95% CI 1.02 – 1.63; P = 0.03).

Conclusions

In breast cancer, previously undiagnosed diabetes is associated with advanced stage cancer and increased mortality. Identifying biological factors would require further investigation.

【 授权许可】

   
2012 Griffiths et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Larsson SC, Mantzoros CS, Wolk A: Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007, 121:856-862.
• [2]Peairs KS, Barone BB, Snyder CF, Yeh H-C, Stein KB, Derr RL, Brancati FL, Wolff AC: Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011, 29(1):40-46.
• [3]Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K: The impact of type 2 diabetes mellitus on cancer-specific survival. Cancer 2012, 118:1353-1361.
• [4]Schrauder MG, Fasching PA, Habërle L, Lux MP, Rauh C, Hein A, Bayer CM, Heusinger K, Hartmann A, Strehl JD, et al.: Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol 2011, 137:975-983.
• [5]Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL, Pierce JP: Clinically defined type 2 diabetes mellitus and prognosis in early stage breast cancer. J Clin Oncol 2011, 29(1):54-60.
• [6]Srokowski TP, Fang S, Hortobagyi GN, Giordano SH: Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009, 27(13):2170-2176.
• [7]Van de Poll-Franse LV, Houterman S, Janssen-Heijnen MLG, Dercksen MW, Coebergh JWW, Haak HR: Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population-based analysis. Int J Cancer 2007, 120:1986-1992.
• [8]Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001, 285(7):885-892.
• [9]Zhou XH, Qiao Q, Zethilius B, Pyörälä K, Söderberg S, Pajak A, Stehouwer CDA, Heine RJ, Jousilahti P, Ruotolo G, for the DECODE Study Group, et al.: Diabetes, prediabetes and cancer mortality. Diabetologia 2010, 53:1867-1876.
• [10]Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM: Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012. Published online June 14, 2012
• [11]Patnaik JL, Byers T, DiGuiseppi C, Dabela D, Denberg TD: Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011, 13:R64. BioMed Central Full Text
• [12]Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008, 109:389-395.
• [13]Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005, 294:1765-1772.
• [14]Du W, Simon MS: Racial disparities in treatment and survival of women with stage I-III breast cancer at a large academic medical center in metropolitan Detroit. Breast Cancer Res Treat 2005, 91:243-248.
• [15]Fleming ST, Rastogi A, Dmitrienko A, Johnson KD: A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999, 37(6):601-614.
• [16]Wolf I, Catane R, Karasik A, Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol 2005, 6:103-111.
• [17]Giovannuci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. Diabetes Care 2010, 33(7):1674-1685.
• [18]DeCensi A, Gennari A: Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011, 29(1):7-10.
• [19]Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS: Screening mammogram utilization in women with diabetes. Diabetes Care 2001, 24(12):2049-2053.
• [20]McBean AM, Yu X: The underuse of screening services among elderly women with diabetes. Diabetes Care 2007, 30(6):1466-1472.
• [21]Keating NL, Landrum MB, Ayanian JZ, Winder EP, Guadagnoli E: The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med 2004, 20:38-44.
• [22]Gornick ME, Eggers PW, Riley GF: Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis. HSR: Health Services Res 2004, 39(5):1403-1427.
• [23]Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K: Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 2005, 43:132-140.
• [24]Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008, 300(23):2754-2764.
• [25]Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM: Identifying persons with diabetes using Medicare claims data. Am J Medical Quality 1999, 14(6):270-277.
• [26]Klabunde CN, Potosky AL, Legler JM, Warren JL: Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000, 53:1258-1267.
• [27]Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, et al.: Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32(2):287-294.
• [28]Danese MD, O’Malley C, Lindquist K, Gleeson M, Griffiths RI: An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol 2011. Epub ahead of print
• [29]Executive summary: standards of medical care in diabetes – 2011 Diabetes Care 2011, 34(suppl. 1):S4-S10.
• [30]Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8(6):909-915.
• [31]Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung M-C, Hortobagyi GN, Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27(20):3297-3302.
• [32]Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003, 157(12):1092-1100.
• [33]Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF: Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-18.
• [34]National Cancer Institute: Overview of the SEER Program [Internet]. Bethesda: National Cancer Institute; 2011. [Accessed 9/29/2011.] Available from: http://seer.cancer.gov/about/overview.html webcite
• [35]National Cancer Institute: Overview of the SEER Program [Internet]. Bethesda: National Cancer Institute; 2011. [Accessed 9/29/2011.] Available from: http://healthservices.cancer.gov/seermedicare/overview/linked.html webcite
• [36]Fritz A, Ries L (Eds): SEER program code manual. 3rd edition. Bethesda: Cancer Statistics Branch, Surveillance Program, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Dept of Health and Human Services; 1998.
• [37]Klabunde CN, Legler JM, Warren JL, Baldwin L-M, Schrag D: A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007, 17:584-590.
• [38]National Cancer Institute: Overview of the SEER Program [Internet]. Bethesda: National Cancer Institute; 2010. [Accessed 8/27/10.] Available from: http://healthservices.cancer.gov/seermedicare/program/remove.ruleout.dxcodes.macro.txt webcite
• [39]National Cancer Institute: Overview of the SEER Program [Internet]. Bethesda: National Cancer Institute; 2010. [Accessed 8/27/10.] Available from: http://healthservices.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt webcite
• [40]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [41]Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619.
• [42]Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K: A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol 1994, 47:249-260.
• [43]Davidoff AJ, Tang M, Seal B, Edelman MJ: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2191-2197.
• [44]Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002, 40(8 Suppl):IV-55-IV-61.
• [45]National Cancer Institute: Procedure Codes for SEER Medicare Analysis [Internet]. Bethesda: National Cancer Institute; 2012. [Accessed 5/17/2012.] Available from: http://healthservices.cancer.gov/seermedicare/considerations/procedure_codes.html webcite
• [46]ResDAC. Research Data Assistance Center: CMS 301: Using SEER/Medicare data for research. MN: ResDAC, Minneapolis; 2008.
• [47]Glymour MM, Greenland S: Causal diagrams. In Modern epidemiology. Third Edition edition. Edited by Rothman KJ, Greenland S, Lash TL. Philadelphia: Lippincott Williams and Wilkins; 2008:183-209.
• [48]Hernán MA, Hernández-Díaz S, Robins JM: A structural approach to selection bias. Epidemiology 2004, 15(5):615-625.
• [49]Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C: llustrating bias due to conditioning on a collider. Int J Epidemiol 2010, 39:417-420.
• [50]Ashkenazy R, Abrahamson MJ: Medicare coverage for patients with diabetes. A national plan with individual consequences. J Gen Intern Med 2006, 21:386-392.